GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Covalon Technologies Ltd (OTCPK:CVALF) » Definitions » 14-Day RSI

Covalon Technologies (Covalon Technologies) 14-Day RSI : 32.19 (As of May. 10, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Covalon Technologies 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-10), Covalon Technologies's 14-Day RSI is 32.19.

The industry rank for Covalon Technologies's 14-Day RSI or its related term are showing as below:

CVALF's 14-Day RSI is ranked better than
57.21% of 1575 companies
in the Biotechnology industry
Industry Median: 48.63 vs CVALF: 32.19

Competitive Comparison of Covalon Technologies's 14-Day RSI

For the Biotechnology subindustry, Covalon Technologies's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Covalon Technologies's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Covalon Technologies's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Covalon Technologies's 14-Day RSI falls into.



Covalon Technologies  (OTCPK:CVALF) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Covalon Technologies  (OTCPK:CVALF) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Covalon Technologies 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Covalon Technologies's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Covalon Technologies (Covalon Technologies) Business Description

Traded in Other Exchanges
Address
1660 Tech Avenue, Unit 5, Mississauga, ON, CAN, L4W 5S7
Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops advanced wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales.